Samsung Bioepis Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Samsung Bioepis Co., Ltd.
The pricing watchdog said 94% of Fabhalta’s price comes from offsetting the cost of AstraZeneca’s Ultomiris, while Novartis said ICER’s analysis has “substantial challenges.”
In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting.
In a rather novel case in Canada, Novartis has established before a Federal district court that there is a likelihood that the trademark rights for its Beovu brand will be confused with Samsung Bioepis and Biogen’s Byooviz biosimilar.
In its latest biosimilar market report, Samsung Bioepis laments the lack of uptake for biosimilar rivals to Humira, despite a slew of challengers arriving in the US last year.
- Large Molecule
- Other Names / Subsidiaries
- Samsung Biologics
- Samsung Bioepis JV
- Samsung Bioepis BR Pharmaceutical LTDA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.